# EDGAR Filing Document

**Accession Number:** 0001494891
**File Stem:** 0001753926-26-000088
**Filing Date:** 2026-1
**Character Count:** 10004
**Document Hash:** a117bf8be9d49858ed92ba4d5d64be71
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001753926-26-000088.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001753926-26-000088

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260105

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sensus Healthcare, Inc.
- **CENTRAL INDEX KEY:** 0001494891
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 271647271
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37714
- **FILM NUMBER:** 26524381

**BUSINESS ADDRESS:**
- **STREET 1:** 851 BROKEN SOUND PARKWAY NW
- **STREET 2:** SUITE 215
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33487
- **BUSINESS PHONE:** 561-922-5808

**MAIL ADDRESS:**
- **STREET 1:** 851 BROKEN SOUND PARKWAY NW
- **STREET 2:** SUITE 215
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33487

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sensus Healthcare, LLC
- **DATE OF NAME CHANGE:** 20100622

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**____________________**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** <u>January 5, 2026</u>

**SENSUS HEALTHCARE, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| Delaware | 001-37714 | 27-1647271 |
| (State of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 851 Broken Sound Pkwy., NW # 215, Boca Raton, Florida | 851 Broken Sound Pkwy., NW # 215, Boca Raton, Florida | 33487 |
| (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: <u>(561) 922-5808</u>

_________________________________________________

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | SRTS | Nasdaq Stock Market, LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**SENSUS HEALTHCARE, INC.**

**FORM 8-K**

**CURRENT REPORT**

**ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

**(d)** On January 5, 2026, the Board of Directors (the "Board") of Sensus Healthcare, Inc. (the "Company") appointed Larry Biscotti as a Class I director of the Company for a term expiring at the Company's annual meeting in 2028.

There are no arrangements or understandings between Mr. Biscotti and any other persons pursuant to which he was elected, nor does he have any direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Securities and Exchange Commission Regulation S-K. As a director of the Company, Mr. Biscotti is expected to receive the same compensation for service as a director as is provided to other non-employee directors of the Company on a pro-rata annual basis. The Board has determined that Mr. Biscotti is an independent director within the meaning of Rule 5605(a)(2) as set forth in the listing standards of The NASDAQ Stock Market, LLC. At the time of the filing of this Current Report, any committee to which Mr. Biscotti may be appointed has not been determined.

On January 7, 2026, the Company issued a press release announcing Mr. Biscotti's election. The press release is filed as an exhibit to this Report. The press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

**(d) Exhibits**

[99.1 Press Release dated January 7, 2026.](g085076_ex99-1.htm)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SENSUS HEALTHCARE, INC.** | **SENSUS HEALTHCARE, INC.** |
| Date:&nbsp;&nbsp;&nbsp;&nbsp; <u>January 9, 2026</u> | By: | <u>/s/ Javier Rampolla&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  |
|  |  | Javier Rampolla |
|  |  | Chief Financial Officer |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | Press Release, dated January 7, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

## Exhibit 99.1

**Exhibit 99.1**

**Sensus Healthcare Appoints Larry Biscotti to its Board of Directors**

BOCA RATON, Fla. - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors.

Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologies. He currently serves as President, Imaging for the U.S. and Canada at GE HealthCare, where he is responsible for the company's largest global product and solutions segment. His prior work history includes positions with Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Medicine, and CTI Molecular Imaging, providing a strong foundation in imaging, oncology and radiation therapy technologies.

"Larry brings to the Sensus Board a wealth of skills, value and complementary experiences. Over the course of his career, he has led multibillion-dollar P&Ls, introduced innovative cancer treatment technologies, built and scaled commercial teams and expanded businesses globally through strategic partnerships and distribution agreements," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "His integrity, judgment and commitment to improving patient outcomes fit well with our culture and mission. I've had the privilege of working with Larry throughout my career and know firsthand the leadership and insight he brings. We are pleased to welcome Larry to our Board as we expand the reach of our SRT technology and execute on our long-term vision."

"I am honored to join the Board of Directors of Sensus Healthcare at a time when patient-centered, non-invasive treatments are becoming increasingly important for a variety of conditions. The company's commitment to innovation, clinical excellence and improving patient outcomes strongly aligns with my own personal values and professional experiences. I look forward to supporting Sensus' continued growth and impact for patients and clinicians," added Mr. Biscotti.

Mr. Biscotti holds an MBA from Pepperdine University and a Bachelor of Science from Cornell University. He is an alumnus of Harvard Business School's Program for Leadership Development.

**About Sensus Healthcare**

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260107574605/en/

**Alliance Advisors IR** <br> Tirth T. Patel <br> tpatel@allianceadvisors.com <br> 212-201-6614